Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

EY Yu; SH Park; JCH Goh; SJ Shin; N Mehra; R McDermott; MAS Gonzalez; PC Fong; Richard Greil; M Retz; JP Sade; YH Huang; S Begbie; F Rey; G Kramer; H Suzuki; J Zhang; J Kim; CH Poehlein; ES Antonarakis

Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

EY Yu, SH Park, JCH Goh, SJ Shin, N Mehra, R McDermott, MAS Gonzalez, PC Fong, Richard Greil, M Retz, JP Sade, YH Huang, S Begbie, F Rey, G Kramer, H Suzuki, J Zhang, J Kim, CH Poehlein, ES Antonarakis

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › published Abstract (Journal) › peer-review

7 Citations (Web of Science)

Original language	English
Pages (from-to)	S1163-S1164
Journal	ANNALS OF ONCOLOGY
Volume	33
Issue number	7
Publication status	Published - 2022
Event	Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) - ELECTR NETWORK Duration: 9 Sept 2022 → 13 Sept 2022

Cite this

Yu, EY., Park, SH., Goh, JCH., Shin, SJ., Mehra, N., McDermott, R., Gonzalez, MAS., Fong, PC., Greil, R., Retz, M., Sade, JP., Huang, YH., Begbie, S., Rey, F., Kramer, G., Suzuki, H., Zhang, J., Kim, J., Poehlein, CH., & Antonarakis, ES. (2022). Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study. ANNALS OF ONCOLOGY , 33(7), S1163-S1164.

Yu, EY ; Park, SH ; Goh, JCH et al. / Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study. In: ANNALS OF ONCOLOGY 2022 ; Vol. 33, No. 7. pp. S1163-S1164.

@article{33c75b7e4abc4c3ea096b9d07a1df6f6,

title = "Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study",

author = "EY Yu and SH Park and JCH Goh and SJ Shin and N Mehra and R McDermott and MAS Gonzalez and PC Fong and Richard Greil and M Retz and JP Sade and YH Huang and S Begbie and F Rey and G Kramer and H Suzuki and J Zhang and J Kim and CH Poehlein and ES Antonarakis",

year = "2022",

language = "English",

volume = "33",

pages = "S1163--S1164",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

number = "7",

note = "Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 09-09-2022 Through 13-09-2022",

}

Yu, EY, Park, SH, Goh, JCH, Shin, SJ, Mehra, N, McDermott, R, Gonzalez, MAS, Fong, PC, Greil, R, Retz, M, Sade, JP, Huang, YH, Begbie, S, Rey, F, Kramer, G, Suzuki, H, Zhang, J, Kim, J, Poehlein, CH & Antonarakis, ES 2022, 'Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study', ANNALS OF ONCOLOGY , vol. 33, no. 7, pp. S1163-S1164.

Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study. / Yu, EY; Park, SH; Goh, JCH et al.
In: ANNALS OF ONCOLOGY , Vol. 33, No. 7, 2022, p. S1163-S1164.

Research output: Contribution to journal › published Abstract (Journal) › peer-review

TY - JOUR

T1 - Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

AU - Yu, EY

AU - Park, SH

AU - Goh, JCH

AU - Shin, SJ

AU - Mehra, N

AU - McDermott, R

AU - Gonzalez, MAS

AU - Fong, PC

AU - Greil, Richard

AU - Retz, M

AU - Sade, JP

AU - Huang, YH

AU - Begbie, S

AU - Rey, F

AU - Kramer, G

AU - Suzuki, H

AU - Zhang, J

AU - Kim, J

AU - Poehlein, CH

AU - Antonarakis, ES

PY - 2022

Y1 - 2022

M3 - published Abstract (Journal)

SN - 0923-7534

VL - 33

SP - S1163-S1164

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

IS - 7

T2 - Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 9 September 2022 through 13 September 2022

ER -

Yu EY, Park SH, Goh JCH, Shin SJ, Mehra N, McDermott R et al. Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study. ANNALS OF ONCOLOGY . 2022;33(7):S1163-S1164.